By John Miller, consultant in pharma market – Eurasia Business News, August 18, 2025. Article no. 1722

China has officially approved the sale of FibroGen China to AstraZeneca. The transaction, initially announced in early 2025, involves AstraZeneca acquiring FibroGen’s China unit for approximately $160 million to gain regional rights to the oral anemia drug roxadustat in China. This approval by China’s State Administration for Market Regulation is a major regulatory milestone for the deal, which remains on track to close in the third quarter of 2025.
Under the terms, AstraZeneca will obtain all rights to roxadustat in China, where the drug is a category leader for treating anemia in chronic kidney disease. This move allows AstraZeneca to expand its foothold in the Chinese market with a strategic asset, while FibroGen will simplify its capital structure and extend its cash runway into 2027 by repaying debt with the proceeds.
The sale is part of a longer-standing partnership between the two companies around roxadustat, which AstraZeneca markets under the brand name Evrenzo in China. The deal reflects AstraZeneca’s confidence in the growth potential of its China business despite recent challenges.
Our community already has 155,000 readers, joins us !
Subscribe to our Telegram channel
Follow us on Telegram, Facebook and Twitter
© Copyright 2025 – Eurasia Business News. Article no. 1722